Comparative Pharmacology
Head-to-head clinical analysis: DERMOTIC versus TRIDESILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMOTIC versus TRIDESILON.
DERMOTIC vs TRIDESILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dermotic (fluocinolone acetonide) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid, thereby suppressing the synthesis of prostaglandins and leukotrienes, leading to anti-inflammatory and immunosuppressive effects.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Each 1 mL contains 1 mg betamethasone valerate, 10 mg neomycin sulfate, 10,000 units polymyxin B sulfate. Apply 3-4 drops into affected ear(s) 2-3 times daily for 7-10 days.
0.05% ointment or cream applied topically to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours. In patients with renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding.
Primarily renal excretion of unchanged drug (approximately 70-80%) with the remainder metabolized and excreted via biliary/fecal routes (20-30%).
Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid